Rossi M L, Buller J R, Heath S A, Carey M P, Carboni P, Koutsoubelis G, Coakham H B
Department of Neuropathology, Midland Centre for Neurosurgery and Neurology, Birmingham, United Kingdom.
Tumori. 1991 Feb 28;77(1):36-40. doi: 10.1177/030089169107700109.
We have studied formalin fixed, paraffin-wax embedded tissue from 35 medulloblastomas, collected over 23 years (27 non-desmoplastic and 8 desmoplastic) with KP1 and Mac387 two monoclonal anti-monocytes/macrophage (M/Ms) antibodies recommended for use on paraffin wax embedded tissue. In non-desmoplastic medulloblastomas, outside areas of necrosis, M/Ms were detected in 50% of cases with KP1 and 52% with Mac387. M/Ms were seen in 100% of desmoplastic medulloblastomas with both antibodies. Semiquantitative assessment revealed that, on average, desmoplastic tumors had at least three times as many infiltrating M/Ms as non-desmoplastic tumors. There was no significant difference in the findings with the two antibodies or, between recently embedded and "older" tumors. The findings may be indicative of the presence of a host M/Ms immune response in medulloblastoma, which may be more accentuated in desmoplastic medulloblastomas. Furthermore, we conclude that these antibodies are quite suitable for the study of infiltrating M/Ms, thus lessening (but not obviating) the need for frozen tissue for immunohistological studies.
我们研究了用福尔马林固定、石蜡包埋的35例髓母细胞瘤组织,这些组织是在23年期间收集的(27例为非促纤维增生性,8例为促纤维增生性),使用了推荐用于石蜡包埋组织的两种单克隆抗单核细胞/巨噬细胞(M/Ms)抗体KP1和Mac387。在非促纤维增生性髓母细胞瘤中,在坏死区域以外,使用KP1抗体在50%的病例中检测到M/Ms,使用Mac387抗体在52%的病例中检测到M/Ms。在100%的促纤维增生性髓母细胞瘤中使用两种抗体均能看到M/Ms。半定量评估显示,平均而言,促纤维增生性肿瘤中浸润的M/Ms数量至少是非促纤维增生性肿瘤的三倍。两种抗体的检测结果之间,以及近期包埋的肿瘤和“陈旧”肿瘤之间均无显著差异。这些结果可能表明髓母细胞瘤中存在宿主M/Ms免疫反应,在促纤维增生性髓母细胞瘤中这种反应可能更明显。此外,我们得出结论,这些抗体非常适合用于研究浸润的M/Ms,从而减少(但并未消除)免疫组织学研究对冷冻组织的需求。